Browse press releases
The newest releases come first, each with its full text here and a link to its original. Try the filters to narrow them down.
- CMS: Initial Prescriptions for Silevimig Injection, the World's First Bispecific Antibody Against Rabies, Issued in ChinaSHENZHEN, Sept 9, 2026 - On 9 September, China Medical System Holdings Limited (867.HK/8A8.SG) (“CMS” or the “Group”) is pleased to announce that the initial prescriptions for the Class 1 innovative drug Silevimig Injection (the “Product”) have recently been issued in multiple hospitals across China, including Beijing Luhe Hospital of Capital Medical University, Wenzhou People’s Hospital, Kaiping Central Hospital, Dongguan Guangji Hospital and Huidong Jilong Ankang Hospital. This marks that the world’s first bispecific antibody for passive immunization against rabies has officially commenced its large-scale clinical application, offering a better solution for urgent post-exposure management against rabies in China. Dual-Epitope Neutralization with Low Dosing, Addressing Clinical Pain Points Silevimig Injection is the world’s first fully human bispecific antibody targeting dual epitopes (G protein epitopes I and III) of the rabies virus, which is consistent with the World Health Organization (“WHO”) recommendation for a “cocktail” therapeutic paradigm. It can effectively neutralize different viral strains or genotypes of the rabies virus, providing immediate protection before the establishment of full protection by active rabies vaccination, and building a critical line of defense against viral infection. The Product is currently the passive immunization product with the smallest dose for rabies (0.05 mg/kg); compared with human rabies immune globulin (“HRIG”), it requires less injection volume and easier administration, which can effectively reduce pain and improve compliance for patient. Manufactured using recombinant technology, the Product is non-plasma-derived and carries no risk of blood-borne infections. It can be manufactured at scale through standardized and stable processes, with controllable production costs, while offering a single active ingredient, consistent quality and minimal batch-to-batch variability. These advantages open up new possibilities for improving the safety, standardized supply and patient accessibility of rabies passive immunization products, with the potential to further increase market penetration. Initial Prescriptions Issued Within About Two Months After Approval, Academic-Driven Commercialization Platform Accelerating Value Realization Silevimig Injection was approved for marketing in China in June 2026. Following the approval, CMS worked closely with its partner Genrix Bio to advance critical workstreams including drug supply, market access and academic promotion, while integrating expert networks and market resources. The inital prescriptions were issued in China within approximately two months, accelerating the translation of innovation outcomes into a clinically accessible new treatment option. Currently, CMS has nine commercialized innovative drugs that are progressively achieving large-scale clinical application across China, accelerating the realization of the clinical value of each quality medicine. Going forward, CMS will remain focused on clinical unmet needs and continue to build a differentiated innovative product portfolio through a dual-track system of in-house R&D and collaborative R&D, accelerating accessibility of quality innovative drugs and taking concrete action to safeguard patients’ lives and health. About Rabies Rabies is an acute zoonotic disease caused by RABV, clinically characterized by aerophobia, hydrophobia, pharyngeal muscle spasms and progressive paralysis[1], with a case-fatality rate approaching 100%. At present, there is no proven treatment for rabies once clinical symptoms appear. Standardized post-exposure management, comprising wound care, vaccination and passive immunization administered as needed, remains the most effective strategy[2]. As vaccine-induced antibodies require 1-2 weeks after the first dose of vaccine injection to reach protective levels, passive immunization provides immediate coverage [1]. According to the National Technical Guidelines for the Rabies Exposure Prophylaxis (2023 Edition), patients with Category III exposure, patients with confirmed Category II exposure involving severe immunodeficiency, and patients with Category II exposure involving wounds to the head or face while the health status of the offending animal cannot be determined should receive passive immunization at the same time as the first dose of rabies vaccine[3]. In China, more than 40 million people are exposed to rabies annually, of whom approximately 40% fall under Category III exposure[1]. However, due to factors such as limited awareness, high price, and restricted accessibility, only about 15% of Category III cases receive passive immunization[1]. Currently, the primary passive immunization option in China is HRIG. However, HRIG must be sourced from healthy donors, making it difficult and costly to obtain. Furthermore, it carries potential risks of blood-borne infections. This has led to a low penetration rate of passive immunization products in China. More Information about Silevimig Injection In a Phase III clinical trial in adults in China, Silevimig Injection met its primary efficacy endpoint, demonstrating non-inferior protective efficacy compared with HRIG, the currently most used passive immunization product in China. The Product provides immediate protection during the early stages of rabies virus exposure without compromising the active immune response induced by vaccination. In addition, a Phase III clinical trial in children and adolescents aged 2 to <18 years is currently ongoing in China. The Product has been granted a patent in China. In September 2025, the Group through subsidiaries of the Company entered into an Exclusive Collaboration Agreement (the “Agreement”) with Chongqing Genrix Biopharmaceutical Co., Ltd. In accordance with the Agreement, the Group has obtained exclusive commercialization rights for the Product in mainland China and exclusive licensing rights for the rest of the Asia-Pacific region, the Middle East and North Africa. The collaboration term extends until ten years after the Product receives the marketing approval in Mainland China (the “Initial Term for the Product”). Unless terminated or dissolved under the terms set forth in the Agreement, the Agreement will automatically renew for successive ten-year periods upon expiration of the Initial Term for the Product. About CMS CMS is an innovative pharmaceutical company focused on the identification, building, and full lifecycle management of differentiated specialty pharmaceuticals. With a dual-engine approach of in-house R&D and collaborative R&D, and leveraging its core capability to build markets and brands from the ground up, the Group enables each medicine to fully realize both its clinical value and commercial value. CMS has established an end-to-end capability loop across the full product lifecycle—precisely identifying quality innovation targets, matching them with optimal development pathways, and efficiently advancing clinical development and registration; developing medical strategies aligned with clinical needs, and driving scaled clinical adoption through a professional academic promotion system and network. CMS focuses on advantaged specialties including cardiovascular-kidney-metabolic, central nervous system, gastroenterology, ophthalmology, and skin health. Through professional academic promotion and academic resources across multiple disease areas, CMS has built sustainable scale advantages in specialties, with its skin health business becoming a leading player in its segment. Meanwhile, CMS continues to strengthen its international replication capabilities, validating the transferability of its business model in emerging markets such as Southeast Asia and the Middle East, and injecting long-term momentum for the Group’s high-quality, sustainable development. Reference: 1. Chinese Center for Disease Control and Prevention. Technical Guidelines for Human Rabies Prevention and Control (2016). https://www.chinacdc.cn/jkyj/crb2/yl/kqb/jswj_kqb/202409/P020240906525420231910.pdf 2. Yin Wenwu, Wang Chuanlin, et al. Expert consensus on rabies exposure prophylaxis [J]. Chinese Journal of Preventive Medicine, 2019, 53(7): 668–679. DOI: 10.3760/cma.j.issn.0253-9624.2019.07.004 3. Chinese Center for Disease Control and Prevention. National Technical Guidelines for the Rabies Exposure Prophylaxis (2023 Edition). https://www.chinacdc.cn/jkyj/crb2/yl/kqb/jswj_kqb/202409/P020240906525421817465.pdf CMS Disclaimer and Forward-Looking Statements This press release is not intended to promote any products to you and is not for advertising purposes. This press release does not recommend any drugs, medical devices and/or indications. If you want to know more about the diagnosis and treatment of specific diseases, please follow the opinions or guidance of your doctor or other medical and health professionals. Any treatment-related decisions made by healthcare professionals should be based on the patient’s specific circumstances and in accordance with the drug package insert. This press release which has been prepared by CMS does not constitute any offer or invitation to purchase or subscribe for any securities, and shall not form the basis for or be relied on in connection with any contract or binding commitment whatsoever. This press release has been prepared by CMS based on information and data which it considers reliable, but CMS makes no representation or warranty, express or implied, whatsoever, and no reliance shall be placed on the truth, accuracy, completeness, fairness and reasonableness of the contents of this press release. Certain matters discussed in this press release may contain statements regarding the Group’s market opportunity and business prospects that are individually and collectively forward-looking statements. Such forward-looking statements are not guarantees of future performance and are subject to known and unknown risks, uncertainties and assumptions that are difficult to predict. Any forward-looking statements and projections made by third parties included in this press release are not adopted by the Group and the Company is not responsible for such third-party statements and projections. Media ContactBrand: China Medical System Holdings Ltd.Contact: CMS Investor RelationsEmail: [email protected]: https://web.cms.net.cn/en/home/
- CMS: Initial Prescriptions for Silevimig Injection, the World's First Bispecific Antibody Against Rabies, Issued in ChinaSHENZHEN, Sept 9, 2026 - On 9 September, China Medical System Holdings Limited (867.HK/8A8.SG) (“CMS” or the “Group”) is pleased to announce that the initial prescriptions for the Class 1 innovative drug Silevimig Injection (the “Product”) have recently been issued in multiple hospitals across China, including Beijing Luhe Hospital of Capital Medical University, Wenzhou People’s Hospital, Kaiping Central Hospital, Dongguan Guangji Hospital and Huidong Jilong Ankang Hospital. This marks that the world’s first bispecific antibody for passive immunization against rabies has officially commenced its large-scale clinical application, offering a better solution for urgent post-exposure management against rabies in China. Dual-Epitope Neutralization with Low Dosing, Addressing Clinical Pain Points Silevimig Injection is the world’s first fully human bispecific antibody targeting dual epitopes (G protein epitopes I and III) of the rabies virus, which is consistent with the World Health Organization (“WHO”) recommendation for a “cocktail” therapeutic paradigm. It can effectively neutralize different viral strains or genotypes of the rabies virus, providing immediate protection before the establishment of full protection by active rabies vaccination, and building a critical line of defense against viral infection. The Product is currently the passive immunization product with the smallest dose for rabies (0.05 mg/kg); compared with human rabies immune globulin (“HRIG”), it requires less injection volume and easier administration, which can effectively reduce pain and improve compliance for patient. Manufactured using recombinant technology, the Product is non-plasma-derived and carries no risk of blood-borne infections. It can be manufactured at scale through standardized and stable processes, with controllable production costs, while offering a single active ingredient, consistent quality and minimal batch-to-batch variability. These advantages open up new possibilities for improving the safety, standardized supply and patient accessibility of rabies passive immunization products, with the potential to further increase market penetration. Initial Prescriptions Issued Within About Two Months After Approval, Academic-Driven Commercialization Platform Accelerating Value Realization Silevimig Injection was approved for marketing in China in June 2026. Following the approval, CMS worked closely with its partner Genrix Bio to advance critical workstreams including drug supply, market access and academic promotion, while integrating expert networks and market resources. The inital prescriptions were issued in China within approximately two months, accelerating the translation of innovation outcomes into a clinically accessible new treatment option. Currently, CMS has nine commercialized innovative drugs that are progressively achieving large-scale clinical application across China, accelerating the realization of the clinical value of each quality medicine. Going forward, CMS will remain focused on clinical unmet needs and continue to build a differentiated innovative product portfolio through a dual-track system of in-house R&D and collaborative R&D, accelerating accessibility of quality innovative drugs and taking concrete action to safeguard patients’ lives and health. About Rabies Rabies is an acute zoonotic disease caused by RABV, clinically characterized by aerophobia, hydrophobia, pharyngeal muscle spasms and progressive paralysis[1], with a case-fatality rate approaching 100%. At present, there is no proven treatment for rabies once clinical symptoms appear. Standardized post-exposure management, comprising wound care, vaccination and passive immunization administered as needed, remains the most effective strategy[2]. As vaccine-induced antibodies require 1-2 weeks after the first dose of vaccine injection to reach protective levels, passive immunization provides immediate coverage [1]. According to the National Technical Guidelines for the Rabies Exposure Prophylaxis (2023 Edition), patients with Category III exposure, patients with confirmed Category II exposure involving severe immunodeficiency, and patients with Category II exposure involving wounds to the head or face while the health status of the offending animal cannot be determined should receive passive immunization at the same time as the first dose of rabies vaccine[3]. In China, more than 40 million people are exposed to rabies annually, of whom approximately 40% fall under Category III exposure[1]. However, due to factors such as limited awareness, high price, and restricted accessibility, only about 15% of Category III cases receive passive immunization[1]. Currently, the primary passive immunization option in China is HRIG. However, HRIG must be sourced from healthy donors, making it difficult and costly to obtain. Furthermore, it carries potential risks of blood-borne infections. This has led to a low penetration rate of passive immunization products in China. More Information about Silevimig Injection In a Phase III clinical trial in adults in China, Silevimig Injection met its primary efficacy endpoint, demonstrating non-inferior protective efficacy compared with HRIG, the currently most used passive immunization product in China. The Product provides immediate protection during the early stages of rabies virus exposure without compromising the active immune response induced by vaccination. In addition, a Phase III clinical trial in children and adolescents aged 2 to <18 years is currently ongoing in China. The Product has been granted a patent in China. In September 2025, the Group through subsidiaries of the Company entered into an Exclusive Collaboration Agreement (the “Agreement”) with Chongqing Genrix Biopharmaceutical Co., Ltd. In accordance with the Agreement, the Group has obtained exclusive commercialization rights for the Product in mainland China and exclusive licensing rights for the rest of the Asia-Pacific region, the Middle East and North Africa. The collaboration term extends until ten years after the Product receives the marketing approval in Mainland China (the “Initial Term for the Product”). Unless terminated or dissolved under the terms set forth in the Agreement, the Agreement will automatically renew for successive ten-year periods upon expiration of the Initial Term for the Product. About CMS CMS is an innovative pharmaceutical company focused on the identification, building, and full lifecycle management of differentiated specialty pharmaceuticals. With a dual-engine approach of in-house R&D and collaborative R&D, and leveraging its core capability to build markets and brands from the ground up, the Group enables each medicine to fully realize both its clinical value and commercial value. CMS has established an end-to-end capability loop across the full product lifecycle—precisely identifying quality innovation targets, matching them with optimal development pathways, and efficiently advancing clinical development and registration; developing medical strategies aligned with clinical needs, and driving scaled clinical adoption through a professional academic promotion system and network. CMS focuses on advantaged specialties including cardiovascular-kidney-metabolic, central nervous system, gastroenterology, ophthalmology, and skin health. Through professional academic promotion and academic resources across multiple disease areas, CMS has built sustainable scale advantages in specialties, with its skin health business becoming a leading player in its segment. Meanwhile, CMS continues to strengthen its international replication capabilities, validating the transferability of its business model in emerging markets such as Southeast Asia and the Middle East, and injecting long-term momentum for the Group’s high-quality, sustainable development. Reference: 1. Chinese Center for Disease Control and Prevention. Technical Guidelines for Human Rabies Prevention and Control (2016). https://www.chinacdc.cn/jkyj/crb2/yl/kqb/jswj_kqb/202409/P020240906525420231910.pdf 2. Yin Wenwu, Wang Chuanlin, et al. Expert consensus on rabies exposure prophylaxis [J]. Chinese Journal of Preventive Medicine, 2019, 53(7): 668–679. DOI: 10.3760/cma.j.issn.0253-9624.2019.07.004 3. Chinese Center for Disease Control and Prevention. National Technical Guidelines for the Rabies Exposure Prophylaxis (2023 Edition). https://www.chinacdc.cn/jkyj/crb2/yl/kqb/jswj_kqb/202409/P020240906525421817465.pdf CMS Disclaimer and Forward-Looking Statements This press release is not intended to promote any products to you and is not for advertising purposes. This press release does not recommend any drugs, medical devices and/or indications. If you want to know more about the diagnosis and treatment of specific diseases, please follow the opinions or guidance of your doctor or other medical and health professionals. Any treatment-related decisions made by healthcare professionals should be based on the patient’s specific circumstances and in accordance with the drug package insert. This press release which has been prepared by CMS does not constitute any offer or invitation to purchase or subscribe for any securities, and shall not form the basis for or be relied on in connection with any contract or binding commitment whatsoever. This press release has been prepared by CMS based on information and data which it considers reliable, but CMS makes no representation or warranty, express or implied, whatsoever, and no reliance shall be placed on the truth, accuracy, completeness, fairness and reasonableness of the contents of this press release. Certain matters discussed in this press release may contain statements regarding the Group’s market opportunity and business prospects that are individually and collectively forward-looking statements. Such forward-looking statements are not guarantees of future performance and are subject to known and unknown risks, uncertainties and assumptions that are difficult to predict. Any forward-looking statements and projections made by third parties included in this press release are not adopted by the Group and the Company is not responsible for such third-party statements and projections. Media Contact Brand: China Medical System Holdings Ltd. Contact: CMS Investor Relations Email: [email protected] Website: https://web.cms.net.cn/en/home/
- TransNusa Launches Maiden Bali-Phuket Flight for the Ultimate Island-Hopping ExperienceIndonesian premium service carrier, TransNusa, today officially launched its maiden nonstop flight between Bali and Phuket, creating a dream pathway for tropical travellers. Flight 8B 541 departed I Gusti Ngurah Rai International Airport this morning at 11.30 AM, seamlessly linking two of Southeast Asia’s most iconic beach destinations. The new route eliminates tedious layovers, turning a previously long travel day into a smooth four-hour flight. "Today we celebrate more than just a new flight; we are bridging two world-class tourism capitals," said Datuk Bernard Francis, TransNusa Group Chief Executive Officer. "As Bali's International Premium Airline, our goal is to design ultimate island experiences that bring the best of sun, sea and healing straight to our passengers. This route was established to boost tourism in the region, create new economic opportunities, and further strengthen TransNusa's hub in Bali. By providing a direct link, we make it easier than ever for global travellers to experience the unique cultures of Phuket, Bali and beyond Bali in a single itinerary," Datuk Francis explained. Datuk Bernard Francis... TransNusa becomes Bali's Premium Airline "Our vision for TransNusa extends far beyond connecting domestic and international corridors or enhancing and enlarging just network connectivity," Datuk Francis explained. "We are committed to unlocking the unparalleled beauty of Indonesia's hidden gems. By expanding our domestic network directly beyond Bali, we are giving global travellers immediate access to pristine, untouched island destinations that showcase the true beauty and paradise of the Indonesian archipelago." Connecting Bali to Indonesia's Hidden Paradises TransNusa has recently started introducing new launches connecting directly island destinations directly with Bali, simultaneously creating new direct routes where non was available before and reducing travelling time by more than half, enabling travellers’ direct access to Indonesia’s hidden gems such Wakatobi, Lombok, Manado, and Bima, which are some of the country’s most spectacular, biodiversity-rich islands: Wakatobi: Globally celebrated for hosting the world's second-largest barrier reef, this remote marine haven is a top spot for world-class diving and pristine underwater ecosystems. Lombok: A premier leisure escape centered on elite wellness programs featuring holistic health retreats, oceanside yoga, and traditional Sasak healing therapies. In addition, Lombok is also known for its pristine coastal and volcanic adventures and high-octane sports tourism like world-class surfing and the Mandalika international racing circuit. Manado: Located in North Sulawesi, this diving destination is framed by dramatic volcanic beauty and serves as the gateway to the world-renowned Bunaken National Marine Park. Bima: Situated on Sumbawa Island, Bima offers rugged landscapes, rich cultural heritage, and serves as an ideal entry point for surfers and adventure seekers looking for raw natural beauty. Expanding Horizons: Gateway to Singapore and Perth Further positioning itself as a key regional player, TransNusa also bridges Bali with major international hubs beyond Thailand. The airline operates highly sought-after routes from Bali to the cosmopolitan global financial hub of Singapore as well as to Perth, marking a highly successful expansion that connects Western Australia directly to the Island of the Gods. Inaugural Flight Schedule & Premium Comfort The new Bali–Phuket route operates four times weekly on Monday, Wednesday, Friday, and Sunday, and will scale up to a daily service beginning October 3, 2026. TransNusa’s scheduled flight, 8B 541, will depart Bali at 11.30 from I Gusti Ngurah International Airport and arrive at the Phuket International Airport at 14.35 while the return flights, 8B 542, will depart the Phuket International Airport at 15.35 and arrive at I Gusti Ngurah International Airport in Bali at 20.35. For the four-hour scheduled flight from Bali to Phuket, TransNusa will be utilising its Airbus A320, which has 174 seats. To celebrate the launch, TransNusa continues to offer introductory promotional fares starting from IDR2,399,000 / USD135 one-way, bookable via the official airline website at transnusa.co.id. Travelers can customize their experience through three-tiered product offerings: SEAT (includes 20kg baggage), SEAT-PLUS, and FLEXI-PRO (includes 30kg baggage, hot meals, priority boarding, and flexible flight changes). About TransNusa TransNusa Airline, is a Premium Service Carrier. In February 2024, the airline rebranded itself to a Premium Service Carrier in line with its upgraded aircrafts that offers better comfort as well as based on the flexibility and quality of the services offered. TransNusa, which received its AOC certification on 9th September 2022, launch its first three A320 operations on 6th October, 14th October and 12th December, 2022. In 2023, TransNusa introduced a new business model making it the first Premium Service Carrier in the Asia Pacific region. TransNusa introduced its first international flight on 14th April, 2023. The airline is currently based in Jakarta and Bali. On the international front, TransNusa flies to Singapore, Guangzhou, Kuala Lumpur, Penang, Perth, Shenzhen and Bangkok. The airline became the second Indonesian airline to fly to China and the first Indonesian airline to launch a Premium Service Carrier business model. Passengers can book their flights on the TransNusa website at www.transnusa.co.id, through any secure online travel agent, through authorized travel agents in Singapore and Indonesia. International Media Contact Email: [email protected] Website: transnusa.co.id. Passengers can purchase tickets directly from TransNusa or any primary online travel agent
- TransNusa Launches Maiden Bali-Phuket Flight for the Ultimate Island-Hopping ExperienceIndonesian premium service carrier, TransNusa, today officially launched its maiden nonstop flight between Bali and Phuket, creating a dream pathway for tropical travellers. Flight 8B 541 departed I Gusti Ngurah Rai International Airport this morning at 11.30 AM, seamlessly linking two of Southeast Asia’s most iconic beach destinations. The new route eliminates tedious layovers, turning a previously long travel day into a smooth four-hour flight. "Today we celebrate more than just a new flight; we are bridging two world-class tourism capitals," said Datuk Bernard Francis, TransNusa Group Chief Executive Officer. "As Bali's International Premium Airline, our goal is to design ultimate island experiences that bring the best of sun, sea and healing straight to our passengers. This route was established to boost tourism in the region, create new economic opportunities, and further strengthen TransNusa's hub in Bali. By providing a direct link, we make it easier than ever for global travellers to experience the unique cultures of Phuket, Bali and beyond Bali in a single itinerary," Datuk Francis explained. Datuk Bernard Francis... TransNusa becomes Bali's Premium Airline "Our vision for TransNusa extends far beyond connecting domestic and international corridors or enhancing and enlarging just network connectivity," Datuk Francis explained. "We are committed to unlocking the unparalleled beauty of Indonesia's hidden gems. By expanding our domestic network directly beyond Bali, we are giving global travellers immediate access to pristine, untouched island destinations that showcase the true beauty and paradise of the Indonesian archipelago." Connecting Bali to Indonesia's Hidden Paradises TransNusa has recently started introducing new launches connecting directly island destinations directly with Bali, simultaneously creating new direct routes where non was available before and reducing travelling time by more than half, enabling travellers’ direct access to Indonesia’s hidden gems such Wakatobi, Lombok, Manado, and Bima, which are some of the country’s most spectacular, biodiversity-rich islands: Wakatobi: Globally celebrated for hosting the world's second-largest barrier reef, this remote marine haven is a top spot for world-class diving and pristine underwater ecosystems. Lombok: A premier leisure escape centered on elite wellness programs featuring holistic health retreats, oceanside yoga, and traditional Sasak healing therapies. In addition, Lombok is also known for its pristine coastal and volcanic adventures and high-octane sports tourism like world-class surfing and the Mandalika international racing circuit. Manado: Located in North Sulawesi, this diving destination is framed by dramatic volcanic beauty and serves as the gateway to the world-renowned Bunaken National Marine Park. Bima: Situated on Sumbawa Island, Bima offers rugged landscapes, rich cultural heritage, and serves as an ideal entry point for surfers and adventure seekers looking for raw natural beauty. Expanding Horizons: Gateway to Singapore and Perth Further positioning itself as a key regional player, TransNusa also bridges Bali with major international hubs beyond Thailand. The airline operates highly sought-after routes from Bali to the cosmopolitan global financial hub of Singapore as well as to Perth, marking a highly successful expansion that connects Western Australia directly to the Island of the Gods. Inaugural Flight Schedule & Premium Comfort The new Bali–Phuket route operates four times weekly on Monday, Wednesday, Friday, and Sunday, and will scale up to a daily service beginning October 3, 2026. TransNusa’s scheduled flight, 8B 541, will depart Bali at 11.30 from I Gusti Ngurah International Airport and arrive at the Phuket International Airport at 14.35 while the return flights, 8B 542, will depart the Phuket International Airport at 15.35 and arrive at I Gusti Ngurah International Airport in Bali at 20.35. For the four-hour scheduled flight from Bali to Phuket, TransNusa will be utilising its Airbus A320, which has 174 seats. To celebrate the launch, TransNusa continues to offer introductory promotional fares starting from IDR2,399,000 / USD135 one-way, bookable via the official airline website at transnusa.co.id. Travelers can customize their experience through three-tiered product offerings: SEAT (includes 20kg baggage), SEAT-PLUS, and FLEXI-PRO (includes 30kg baggage, hot meals, priority boarding, and flexible flight changes). About TransNusa TransNusa Airline, is a Premium Service Carrier. In February 2024, the airline rebranded itself to a Premium Service Carrier in line with its upgraded aircrafts that offers better comfort as well as based on the flexibility and quality of the services offered. TransNusa, which received its AOC certification on 9th September 2022, launch its first three A320 operations on 6th October, 14th October and 12th December, 2022. In 2023, TransNusa introduced a new business model making it the first Premium Service Carrier in the Asia Pacific region. TransNusa introduced its first international flight on 14th April, 2023. The airline is currently based in Jakarta and Bali. On the international front, TransNusa flies to Singapore, Guangzhou, Kuala Lumpur, Penang, Perth, Shenzhen and Bangkok. The airline became the second Indonesian airline to fly to China and the first Indonesian airline to launch a Premium Service Carrier business model. Passengers can book their flights on the TransNusa website at www.transnusa.co.id, through any secure online travel agent, through authorized travel agents in Singapore and Indonesia. International Media Contact Email: [email protected] Website: transnusa.co.id. Passengers can purchase tickets directly from TransNusa or any primary online travel agent
- New York State Fair’s 800-Pound Butter Sculpture Recycled Into Energy at Western New York Dairy FarmNew York State Fair’s 800-pound butter sculpture gets a second life as renewable energy, powering homes and businesses at a Western New York dairy farm.
- Kadant Named to Newsweek's List of America's Greatest Companies 2026Kadant Inc. (NYSE: KAI) has been named to Newsweek's list of America's Greatest Companies 2026, recognizing organizations that excel in financial performance, workplace culture, innovation, and sustainability.
- Green Circle Decarbonize Technology Limited Entering into Strategic Partnership Agreement for Mass Production of BocaPCM-TES Panels in the People's Republic of ChinaGreen Circle Decarbonize Technology Limited (the “Company”) (NYSE:GCDT), a premier provider of customized energy-saving solutions, today announced it has entered into a strategic partnership agreement (“Partnership Agreement”) with SANVO Fine Chemicals Group Limited (“SANVO”).
- OracleOracle Announces up to $1 Million for Research into Carbon Capture and Sequestration in New MexicoCompanies: Oracle CorporationAustin, Texas—Sep 8, 2026 Oracle today announced up to $1 million in funding to support research into the potential for carbon capture and sequestration (CCS) at Project Jupiter and across New Mexico. The research will examine how carbon dioxide associated with Bloom Energy fuel cells could be captured safely and efficiently, create a pathway for permanent storage, and a viable commercial model for transportation and
- 应届生举报引发ESG危机，星宇股份还能在港交所上市吗？来源 小兵研究 一、事件始末 星宇股份 为国内汽车车灯A股龙头上市公司（601799），正推进A+H港股上市申报工作。2025年秋季校招，公司面向2026届毕业生大规模放出研发、技术、管培岗位，合计招录了以硕士研究生为主的440名应届生，招聘宣讲时也明确仅安排1个月车间轮岗，结束后回归技术岗位。2026年7月，该批学生正式入职，但入职仅1个月就被人力资源部门集中约谈，要么签署个人原因主动离职协议，公司正常结算工资并额外补偿半个月薪资；要么调岗至流水线、薪资按照一线操作工标准核算，谈话过程中甚至还出现以行业背调、HR圈子施压威胁的情形。 该事件最终导致107名应届生解除劳动合同，该批毕业生不仅错过了秋招黄金期，而且还丢失了去考公考研的应届生身份，心中的委屈可想而知。 学生们留存完整录音、劳动合同、offer等证据，但没有循规蹈矩的去走什么劳动仲裁，而是整理成中英文举报材料直接走港交所ESG申诉通道、欧盟供应链合规体系以及奔驰、宝马
- Crealights and GlobalFoundries Deepen Global Strategic PartnershipHONGKONG/BEIJING, Sept 8, 2026 - September 7, 2026, Crealights (01191.HK) today officially announced a landmark partnership, establishing a long-term, in-depth strategic collaboration with GlobalFoundries (NASDAQ: GFS, "GF"), a leading global semiconductor manufacturer. Leveraging GF's industry-leading silicon photonics technology, Crealights will vigorously advance the engineering deployment and mass production of its 6.4T NPO (Near-Package Optics) products, accelerating the industrialization of next-generation AI silicon photonic interconnect technologies. This strategic move will empower Crealights to consolidate its domestic market position while continuously expanding its footprint in North America and its global business landscape, marking a new phase in the company's global commercialization journey. Currently, global AI computing clusters are rapidly evolving from horizontal scaling (Scale-out) to vertical scaling (Scale-up). Facing the extreme demands of 10,000-card-scale hyperscale data centers for bandwidth density, power efficiency, and latency, Near-Package Optics (NPO) and Co-Packaged Optics (CPO) have emerged as mainstream solutions to overcome next-generation AI interconnect bottlenecks. By integrating and packaging the optical engine directly adjacent to the compute chip, these technologies significantly shorten the optoelectronic signal transmission path. Backed by its comprehensive and mature full-stack silicon photonic technology moat in both NPO and CPO, Crealights has taken the lead in launching 3.2T and 6.4T NPO optical engine products, demonstrating a robust technological advantage in next-generation high-speed AI interconnects. To comprehensively solidify the technological foundation for high-density optical interconnects in next-generation AI systems, Crealights has entered into a deep partnership with GlobalFoundries (GF). By deeply integrating GF's silicon photonics platform with SCALE™ Co-Packaged Optics (CPO) solutions, Crealights continues to build a comprehensive advantage integrating photonic integration, high-performance RF CMOS, advanced optical devices, and fiber optic connectivity. Currently, Crealights is collaborating with GF to establish a broad ecosystem of partners spanning design, packaging, connectivity, and system layers, fully supporting the deployment and implementation of diverse next-generation optical architectures. Meanwhile, leveraging GF’s scalable global manufacturing footprint and proven high-volume production capabilities, Crealights has established a "dual-track" global manufacturing system that operates in parallel both domestically and internationally. Through the efficient synergy of capacity at home and abroad, this strong alliance has not only significantly shortened the R&D cycle for next-generation optical interconnect products, but also achieved end-to-end integration across the entire chain—from local chip design to scaled delivery for customers in North America and worldwide. Together, they are paving a clear path from technology development to large-scale commercialization, effectively addressing the increasingly urgent demand for optical connectivity in AI computing clusters and hyperscale data centers. A spokesperson for Crealights stated: "Having consolidated our position in the domestic AI computing infrastructure market, Crealights is now driving its global expansion with core NPO and CPO technologies. Adding GF's global manufacturing network and silicon photonics process technology to our current silicon photonics ecosystem ensures a stable supply of next-generation silicon photonic products and completes the commercial closed-loop from local R&D to global delivery, continuously providing core interconnect solutions for large-scale AI computing clusters worldwide." Thomas Barber, Vice President of Communications Infrastructure and Data Center End Markets at GlobalFoundries, commented: "Crealights' comprehensive full-stack silicon photonic design capabilities are highly aligned with GF's strengths in scaled wafer manufacturing. Through global capacity synergy and advanced packaging technology empowerment, both parties will drive the large-scale market deployment of Crealights' products in North America and globally, jointly promoting the widespread application of silicon photonic technology in global AI computing infrastructure." Looking ahead, Crealights will continue to deepen their collaboration with GF across three key areas: joint R&D of cutting-edge technologies, global manufacturing capacity synergy, and the industrialization of NPO and CPO, as well as the co-building of the industry ecosystem. This will drive the global scaled deployment of silicon photonic solutions, unlocking more technological possibilities for AI-driven diverse application scenarios. About Crealights Crealights is a globally leading provider of AI silicon photonic interconnect solutions, dedicated to delivering high-speed, low-power optical interconnect products for AI data centers and hyperscale computing clusters. The company possesses end-to-end technical capabilities spanning silicon photonic chip design, wafer testing, and optical module manufacturing. Its core product portfolio covers 400G, 800G and 1.6T optical modules, Active Optical Cables (AOC), as well as NPO and CPO optical engines. Backed by its deep domestic industry foundation and global capacity layout, Crealights has become a key player in global AI computing interconnects.For more information, visit www.crealights.com. About GlobalFoundries GlobalFoundries (GF) is a leading manufacturer of essential semiconductors, enabling AI at scale from the cloud to the physical world. Through deep partnerships with customers, GF delivers differentiated, power-efficient and high-performance solutions for automotive, aerospace and defense, data center, smart mobile devices, internet of things and other high-growth markets. With global manufacturing operations across the U.S., Europe and Asia, GF is a trusted and holistic technology partner for customers around the world. GF’s talented, global team remains focused every day on security, longevity and sustainability. For more information, please follow the WeChat Official Account: GLOBALFOUNDRIES_CN. Media Contact Ms. Claire ZhangTEL: (852) 5427 3696E-mail: [email protected]
- Lerøy Seafood Group ASA – Green bond mandate announcementLerøy Seafood Group ASA, rated BBB/Stable by Nordic Credit Rating, has mandated Danske Bank and DNB Carnegie as Joint Bookrunners to explore the potential issuance of new senior unsecured green bonds. Subject to inter alia market conditions, NOK-denominated fixed and/or floating rate bonds with an expected tenor of 6 years and an expected size of NOK 750 million may follow.
- Crealights and GlobalFoundries Deepen Global Strategic PartnershipHONGKONG/BEIJING, Sept 8, 2026 - September 7, 2026, Crealights (01191.HK) today officially announced a landmark partnership, establishing a long-term, in-depth strategic collaboration with GlobalFoundries (NASDAQ: GFS, "GF"), a leading global semiconductor manufacturer. Leveraging GF's industry-leading silicon photonics technology, Crealights will vigorously advance the engineering deployment and mass production of its 6.4T NPO (Near-Package Optics) products, accelerating the industrialization of next-generation AI silicon photonic interconnect technologies. This strategic move will empower Crealights to consolidate its domestic market position while continuously expanding its footprint in North America and its global business landscape, marking a new phase in the company's global commercialization journey. Currently, global AI computing clusters are rapidly evolving from horizontal scaling (Scale-out) to vertical scaling (Scale-up). Facing the extreme demands of 10,000-card-scale hyperscale data centers for bandwidth density, power efficiency, and latency, Near-Package Optics (NPO) and Co-Packaged Optics (CPO) have emerged as mainstream solutions to overcome next-generation AI interconnect bottlenecks. By integrating and packaging the optical engine directly adjacent to the compute chip, these technologies significantly shorten the optoelectronic signal transmission path. Backed by its comprehensive and mature full-stack silicon photonic technology moat in both NPO and CPO, Crealights has taken the lead in launching 3.2T and 6.4T NPO optical engine products, demonstrating a robust technological advantage in next-generation high-speed AI interconnects. To comprehensively solidify the technological foundation for high-density optical interconnects in next-generation AI systems, Crealights has entered into a deep partnership with GlobalFoundries (GF). By deeply integrating GF's silicon photonics platform with SCALE™ Co-Packaged Optics (CPO) solutions, Crealights continues to build a comprehensive advantage integrating photonic integration, high-performance RF CMOS, advanced optical devices, and fiber optic connectivity. Currently, Crealights is collaborating with GF to establish a broad ecosystem of partners spanning design, packaging, connectivity, and system layers, fully supporting the deployment and implementation of diverse next-generation optical architectures. Meanwhile, leveraging GF’s scalable global manufacturing footprint and proven high-volume production capabilities, Crealights has established a "dual-track" global manufacturing system that operates in parallel both domestically and internationally. Through the efficient synergy of capacity at home and abroad, this strong alliance has not only significantly shortened the R&D cycle for next-generation optical interconnect products, but also achieved end-to-end integration across the entire chain—from local chip design to scaled delivery for customers in North America and worldwide. Together, they are paving a clear path from technology development to large-scale commercialization, effectively addressing the increasingly urgent demand for optical connectivity in AI computing clusters and hyperscale data centers. A spokesperson for Crealights stated: "Having consolidated our position in the domestic AI computing infrastructure market, Crealights is now driving its global expansion with core NPO and CPO technologies. Adding GF's global manufacturing network and silicon photonics process technology to our current silicon photonics ecosystem ensures a stable supply of next-generation silicon photonic products and completes the commercial closed-loop from local R&D to global delivery, continuously providing core interconnect solutions for large-scale AI computing clusters worldwide." Thomas Barber, Vice President of Communications Infrastructure and Data Center End Markets at GlobalFoundries, commented: "Crealights' comprehensive full-stack silicon photonic design capabilities are highly aligned with GF's strengths in scaled wafer manufacturing. Through global capacity synergy and advanced packaging technology empowerment, both parties will drive the large-scale market deployment of Crealights' products in North America and globally, jointly promoting the widespread application of silicon photonic technology in global AI computing infrastructure." Looking ahead, Crealights will continue to deepen their collaboration with GF across three key areas: joint R&D of cutting-edge technologies, global manufacturing capacity synergy, and the industrialization of NPO and CPO, as well as the co-building of the industry ecosystem. This will drive the global scaled deployment of silicon photonic solutions, unlocking more technological possibilities for AI-driven diverse application scenarios. About Crealights Crealights is a globally leading provider of AI silicon photonic interconnect solutions, dedicated to delivering high-speed, low-power optical interconnect products for AI data centers and hyperscale computing clusters. The company possesses end-to-end technical capabilities spanning silicon photonic chip design, wafer testing, and optical module manufacturing. Its core product portfolio covers 400G, 800G and 1.6T optical modules, Active Optical Cables (AOC), as well as NPO and CPO optical engines. Backed by its deep domestic industry foundation and global capacity layout, Crealights has become a key player in global AI computing interconnects.For more information, visit www.crealights.com. About GlobalFoundries GlobalFoundries (GF) is a leading manufacturer of essential semiconductors, enabling AI at scale from the cloud to the physical world. Through deep partnerships with customers, GF delivers differentiated, power-efficient and high-performance solutions for automotive, aerospace and defense, data center, smart mobile devices, internet of things and other high-growth markets. With global manufacturing operations across the U.S., Europe and Asia, GF is a trusted and holistic technology partner for customers around the world. GF’s talented, global team remains focused every day on security, longevity and sustainability. For more information, please follow the WeChat Official Account: GLOBALFOUNDRIES_CN. Media Contact Ms. Claire Zhang TEL: (852) 5427 3696 E-mail: [email protected]